Micol (Galantamine)

Galantamine works by reversibly inhibiting acetylcholinesterase, the enzyme that breaks down acetylcholine, thereby increasing acetylcholine levels. It also allosterically modulates nicotinic acetylcholine receptors, further supporting cholinergic signaling that is reduced in Alzheimer’s disease.

The dosage of Micol is individualized by the prescribing clinician based on the patient’s age, renal and hepatic function, and tolerability. The prescriber determines the appropriate starting dose and any subsequent titration.

Safety of galantamine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Micol, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Micol (galantamine) belongs to the acetylcholinesterase inhibitor class, similar to donepezil and rivastigmine. While all increase acetylcholine, galantamine also modulates nicotinic receptors, which may offer a slightly different side‑effect profile. Choice of therapy depends on efficacy, tolerability, patient comorbidities and clinician preference.

Micol should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Micol is taken orally, usually with food to reduce gastrointestinal upset. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include bradycardia or heart block, severe liver injury, seizures, hallucinations, and rare allergic reactions such as angioedema or anaphylaxis. Patients should be monitored for these events, especially during dose escalation.

Micol should be avoided in patients with known hypersensitivity to galantamine, severe cardiac conduction disorders (e.g., sick‑sinus syndrome, second‑ or third‑degree AV block), uncontrolled asthma or COPD, and those taking potent anticholinergic medications that would negate its effect.